Neurology

Latest News

The long-term data from DELIVER showed meaningful, sustained improvements in functional outcomes and dystrophin expression, as well as a favorable safety profile in patients with Duchenne muscular dystrophy. | Image credit: OlegKachura - stock.adobe.com
DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

August 13th 2025

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).

Following an investigation, the FDA confirmed that shipments of delandistrogene moxeparvovec can resume. | Image Credit: immimagery - stock.adobe.com
FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

July 31st 2025

cognition and alzheimer's disease/dementia | Image credit: Orawan - stock.adobe.com
Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias

July 30th 2025

kid with MS and doctor | Image credit: Halfpoint - stock.adobe.com
Emerging Strategies to Manage Pediatric-Onset Multiple Sclerosis

July 30th 2025

The authors reported robust correlations between composite mean greyscale values and key functional outcomes in DMD. | Image Credit: hafakot - stock.adobe.com
Quantitative Muscle Ultrasound a Promising Noninvasive Biomarker for DMD

July 29th 2025

More News

Blue stamp of FDA approval | Image Credit: argus-stock.adobe.com
June 20th 2024

FDA Grants 2 Approvals to Delandistrogene Moxeparvovec for DMD

Maggie L. Shaw
Accelerated approval was originally granted in June 2023 for patients aged 4 to 5 years, indicating there was an unmet clinical need for a potentially life-saving treatment for the rare genetic muscle disorder.
A panel of 5 experts on Alzheimer disease
June 19th 2024

Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

Derek van Amerongen, MD, MS Soeren Mattke, MD, DSc B. Joy Snider, MD, PhD Kavita V. Nair, PhD Maria Lopes, MD, MS
An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
A panel of 5 experts on Alzheimer disease
June 19th 2024

Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

Derek van Amerongen, MD, MS Soeren Mattke, MD, DSc B. Joy Snider, MD, PhD Kavita V. Nair, PhD Maria Lopes, MD, MS
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.
<12

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo